Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18149683 | 1.00 | GPR119 (0.54) | GPR119MAP4K4HDAC1CHRM4PIK3CD | |
| SCHEMBL31181001 | 0.88 | GPR119 (0.55) | GPR119MAP4K4HDAC1PIK3CDSUV39H2 | |
| SCHEMBL4584304 | 0.87 | GPR119 (0.52) | GPR119MAP4K4HDAC1CHRM4PIK3CD | |
| SCHEMBL4584302 | 0.87 | GPR119 (0.52) | GPR119MAP4K4HDAC1CHRM4PIK3CD | |
| SCHEMBL1448125 | 0.85 | GPR119 (0.61) | GPR119MAP4K4HDAC1SUV39H2MAPT | |
| SCHEMBL12740848 | 0.85 | GPR119 (0.61) | GPR119MAP4K4HDAC1SUV39H2MAPT | |
| SCHEMBL1448124 | 0.85 | GPR119 (0.61) | GPR119MAP4K4HDAC1SUV39H2MAPT | |
| SCHEMBL23560775 | 0.84 | GPR119 (0.62) | GPR119MAP4K4HDAC1SUV39H2MAPT | |
| SCHEMBL1448169 | 0.82 | GPR119 (0.65) | GPR119MAP4K4HDAC1SUV39H2MAPT | |
| SCHEMBL12740835 | 0.82 | GPR119 (0.65) | GPR119MAP4K4HDAC1SUV39H2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | GPR119 976/4885MAP4K4 170/4885HDAC1 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.